Inicio
Resultado de la búsqueda
4 búsqueda de la palabra clave 'refractory epilepsy'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Deep Brain Stimulation and Drug-Resistant Epilepsy: A Review of the Literature / Lady Diana Ladino Malagón
Título : Deep Brain Stimulation and Drug-Resistant Epilepsy: A Review of the Literature Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Fecha de publicación : 2019 Títulos uniformes : Frontiers in Neurology Idioma : Inglés (eng) Palabras clave : Anterior thalamic nucleus electrical stimulation neuromodulation neurostimulation refractory epilepsy target Resumen : Introduction: Deep brain stimulation is a safe and effective neurointerventional technique for the treatment of movement disorders. Electrical stimulation of subcortical structures may exert a control on seizure generators initiating epileptic activities. The aim of this review is to present the targets of the deep brain stimulation for the treatment of drug-resistant epilepsy. Methods: We performed a structured review of the literature from 1980 to 2018 using Medline and PubMed. Articles assessing the impact of deep brain stimulation on seizure frequency in patients with DRE were selected. Meta-analyses, randomized controlled trials, and observational studies were included. Results: To date, deep brain stimulation of various neural targets has been investigated in animal experiments and humans. This article presents the use of stimulation of the anterior and centromedian nucleus of the thalamus, hippocampus, basal ganglia, cerebellum and hypothalamus. Anterior thalamic stimulation has demonstrated efficacy and there is evidence to recommend it as the target of choice. Conclusion: Deep brain stimulation for seizures may be an option in patients with drug-resistant epilepsy. Anterior thalamic nucleus stimulation could be recommended over other targets. Mención de responsabilidad : Nasser Zangiabadi, Lady Diana Ladino, Farzad Sina, Juan Pablo Orozco-Hernández, Alexandra Carter, José Francisco Téllez-Zenteno Referencia : Front Neurol. 2019 Jun 6;10:601. DOI (Digital Object Identifier) : 10.3389/fneur.2019.00601 PMID : 31244761 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fneur.2019.00601/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4245 Deep Brain Stimulation and Drug-Resistant Epilepsy: A Review of the Literature [documento electrónico] / Lady Diana Ladino Malagón, . - 2019.
Obra : Frontiers in Neurology
Idioma : Inglés (eng)
Palabras clave : Anterior thalamic nucleus electrical stimulation neuromodulation neurostimulation refractory epilepsy target Resumen : Introduction: Deep brain stimulation is a safe and effective neurointerventional technique for the treatment of movement disorders. Electrical stimulation of subcortical structures may exert a control on seizure generators initiating epileptic activities. The aim of this review is to present the targets of the deep brain stimulation for the treatment of drug-resistant epilepsy. Methods: We performed a structured review of the literature from 1980 to 2018 using Medline and PubMed. Articles assessing the impact of deep brain stimulation on seizure frequency in patients with DRE were selected. Meta-analyses, randomized controlled trials, and observational studies were included. Results: To date, deep brain stimulation of various neural targets has been investigated in animal experiments and humans. This article presents the use of stimulation of the anterior and centromedian nucleus of the thalamus, hippocampus, basal ganglia, cerebellum and hypothalamus. Anterior thalamic stimulation has demonstrated efficacy and there is evidence to recommend it as the target of choice. Conclusion: Deep brain stimulation for seizures may be an option in patients with drug-resistant epilepsy. Anterior thalamic nucleus stimulation could be recommended over other targets. Mención de responsabilidad : Nasser Zangiabadi, Lady Diana Ladino, Farzad Sina, Juan Pablo Orozco-Hernández, Alexandra Carter, José Francisco Téllez-Zenteno Referencia : Front Neurol. 2019 Jun 6;10:601. DOI (Digital Object Identifier) : 10.3389/fneur.2019.00601 PMID : 31244761 Derechos de uso : CC BY En línea : https://www.frontiersin.org/articles/10.3389/fneur.2019.00601/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4245 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001225 AC-2019-014 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2019-014.pdfAdobe Acrobat PDF Risk factors associated with drug resistant focal epilepsy in adults: A case control study / Lady Diana Ladino Malagón
Título : Risk factors associated with drug resistant focal epilepsy in adults: A case control study Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Fecha de publicación : 2019 Títulos uniformes : Seizure Idioma : Inglés (eng) Palabras clave : Complex partial seizure Focal seizure Intractable epilepsy Refractory epilepsy Risk factor Temporal lobe epilepsy Resumen : Purpose: Using an adult cohort of patients with focal epilepsy, we aimed to identify risk factors for development of drug-resistant epilepsy, which if identifiable would allow patients to receive appropriate counsel and earlier surgical treatment. Methods: This is a case-control study nested within a cohort, 146 adult patients with focal epilepsy were included. Definitions were used in accordance with ILAE criteria. The odds ratio and its confidence interval were calculated. We performed a logistic regression analysis. Results: Seventy-one [48.6%] patients met the criteria for drug-resistant epilepsy [cases] and 75 [51.4%] patients were controls. The mean age of patients was 44.5 ± 16.4 years. The most significant variables associated with developing drug-resistant epilepsy include younger age at diagnosis [18.75 vs. 32.2, p Mención de responsabilidad : Pragma Laboni Roy, Lizbeth Hernandez Ronquillo, Lady Diana Ladino, Jose F Tellez-Zenteno Referencia : Seizure. 2019;73:46–50. DOI (Digital Object Identifier) : 10.1016/j.seizure.2019.10.020 PMID : 31734466 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1059-1311(19)30390-5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5081 Risk factors associated with drug resistant focal epilepsy in adults: A case control study [documento electrónico] / Lady Diana Ladino Malagón, . - 2019.
Obra : Seizure
Idioma : Inglés (eng)
Palabras clave : Complex partial seizure Focal seizure Intractable epilepsy Refractory epilepsy Risk factor Temporal lobe epilepsy Resumen : Purpose: Using an adult cohort of patients with focal epilepsy, we aimed to identify risk factors for development of drug-resistant epilepsy, which if identifiable would allow patients to receive appropriate counsel and earlier surgical treatment. Methods: This is a case-control study nested within a cohort, 146 adult patients with focal epilepsy were included. Definitions were used in accordance with ILAE criteria. The odds ratio and its confidence interval were calculated. We performed a logistic regression analysis. Results: Seventy-one [48.6%] patients met the criteria for drug-resistant epilepsy [cases] and 75 [51.4%] patients were controls. The mean age of patients was 44.5 ± 16.4 years. The most significant variables associated with developing drug-resistant epilepsy include younger age at diagnosis [18.75 vs. 32.2, p Mención de responsabilidad : Pragma Laboni Roy, Lizbeth Hernandez Ronquillo, Lady Diana Ladino, Jose F Tellez-Zenteno Referencia : Seizure. 2019;73:46–50. DOI (Digital Object Identifier) : 10.1016/j.seizure.2019.10.020 PMID : 31734466 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1059-1311(19)30390-5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5081 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001311 AC-2020-015 Archivo digital Producción Científica Artículos científicos Disponible Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review / Lady Diana Ladino Malagón
Título : Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Fecha de publicación : 2018 Títulos uniformes : Seizure Idioma : Inglés (eng) Palabras clave : Adds-on therapy behavior efficacy refractory epilepsy safety side effect Resumen : Purpose: Lacosamide, is one of the newer antiepileptic drug approved for focal drug-resistant epilepsy as an add-on treatment in patients older than 16 years. However, there is growing evidence of its use, safety and efficacy in children. We aim to evaluate efficacy and tolerability of lacosamide in focal and generalized drug-resistant epilepsy and refractory status epilepticus in the pediatric population. Methods: We conducted a systematic review on MEDLINE, EMBASE, COCHRANE, Google Scholar and Scielo from January 2008 to January 2017. The primary outcome was the efficacy of lacosamide in children with drug-resistant epilepsy and refractory status epilepticus. Efficacy and adverse events attributed to lacosamide were extracted from each publication and systematically reported. We performed no meta-analyses due to limited available data. Results: Of 175 abstracts identified by the search, 82 were reviewed as full-text. Twenty-six articles fulfilled eligibility criteria and described outcomes in 797 patients (57% male). The majority of studies were retrospective (69%) small series (84%). On average 51% of patients had 50% or greater seizure reduction. The mean seizure freedom rate was 24%. Adverse effects occurred in 18–59% of patients. The main events were dizziness, sedation, gastrointestinal upset, mood and behavioral changes. Half of the patients with Lennox Gastaut syndrome showed 50% or greater seizure reduction, 32% did not response to lacosamide and 17% suffered seizure aggravation. Conclusion: Current evidence shows lacosamide as a good option in pediatric patients with focal drug-resistant epilepsy and refractory status epilepticus as an add-on therapy given its efficacy on seizure control and safety profile. The use of lacosamide in Lennox-Gastaut syndrome shows conflicting data. Large randomized controlled studies in the pediatric population are necessary to substantiate these findings. Mención de responsabilidad : Johann Sebastián Ortiz de la Rosa, Lady Diana Ladino, Paula Juliana Rodríguez, María Camila Rueda, Juan Pablo Polanía, Angie Catalina Castañeda Referencia : Seizure. 2018 Mar;56:34-40. DOI (Digital Object Identifier) : 10.1016/j.seizure.2018.01.014 PMID : 29428899 En línea : https://www.seizure-journal.com/article/S1059-1311(17)30689-1/fulltext Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4191 Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review [documento electrónico] / Lady Diana Ladino Malagón, . - 2018.
Obra : Seizure
Idioma : Inglés (eng)
Palabras clave : Adds-on therapy behavior efficacy refractory epilepsy safety side effect Resumen : Purpose: Lacosamide, is one of the newer antiepileptic drug approved for focal drug-resistant epilepsy as an add-on treatment in patients older than 16 years. However, there is growing evidence of its use, safety and efficacy in children. We aim to evaluate efficacy and tolerability of lacosamide in focal and generalized drug-resistant epilepsy and refractory status epilepticus in the pediatric population. Methods: We conducted a systematic review on MEDLINE, EMBASE, COCHRANE, Google Scholar and Scielo from January 2008 to January 2017. The primary outcome was the efficacy of lacosamide in children with drug-resistant epilepsy and refractory status epilepticus. Efficacy and adverse events attributed to lacosamide were extracted from each publication and systematically reported. We performed no meta-analyses due to limited available data. Results: Of 175 abstracts identified by the search, 82 were reviewed as full-text. Twenty-six articles fulfilled eligibility criteria and described outcomes in 797 patients (57% male). The majority of studies were retrospective (69%) small series (84%). On average 51% of patients had 50% or greater seizure reduction. The mean seizure freedom rate was 24%. Adverse effects occurred in 18–59% of patients. The main events were dizziness, sedation, gastrointestinal upset, mood and behavioral changes. Half of the patients with Lennox Gastaut syndrome showed 50% or greater seizure reduction, 32% did not response to lacosamide and 17% suffered seizure aggravation. Conclusion: Current evidence shows lacosamide as a good option in pediatric patients with focal drug-resistant epilepsy and refractory status epilepticus as an add-on therapy given its efficacy on seizure control and safety profile. The use of lacosamide in Lennox-Gastaut syndrome shows conflicting data. Large randomized controlled studies in the pediatric population are necessary to substantiate these findings. Mención de responsabilidad : Johann Sebastián Ortiz de la Rosa, Lady Diana Ladino, Paula Juliana Rodríguez, María Camila Rueda, Juan Pablo Polanía, Angie Catalina Castañeda Referencia : Seizure. 2018 Mar;56:34-40. DOI (Digital Object Identifier) : 10.1016/j.seizure.2018.01.014 PMID : 29428899 En línea : https://www.seizure-journal.com/article/S1059-1311(17)30689-1/fulltext Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4191 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000805 AC-2018-092 Archivo digital Producción Científica Artículos científicos Disponible Clinical Benefit of 3 Tesla Magnetic Resonance Imaging Rescanning in Patients With Focal Epilepsy and Negative 1.5 Tesla Magnetic Resonance Imaging / Lady Diana Ladino Malagón
Título : Clinical Benefit of 3 Tesla Magnetic Resonance Imaging Rescanning in Patients With Focal Epilepsy and Negative 1.5 Tesla Magnetic Resonance Imaging Tipo de documento : documento electrónico Autores : Lady Diana Ladino Malagón, Fecha de publicación : 2016 Títulos uniformes : Revista de Investigación Clínica Idioma : Inglés (eng) Palabras clave : Epilepsy surgery lesional epilepsy magnetic resonance imaging partial epilepsy refractory epilepsy 3 Tesla Resumen : Background: Magnetic resonance imaging is an essential tool in the pre-surgical evaluation of patients with drug-resistant epilepsy. Objective: Our aim was to assess the value of re-imaging patients with focal drug-resistant epilepsy. Methods: Thirty patients with negative or non-conclusive 1.5 Tesla magnetic resonance imaging were rescanned with 1.5T and 3T. All of them had previous 1.5 scans with no seizure protocol in a non-specialized center. Two neuroradiologists who were blinded to prior imaging results randomly reviewed the magnetic resonance images. Kappa score was used to assess the reliability. Results: Mean age of patients was 30 (SD ± 11) years. The intra-observer agreement for the first radiologist was 0.74 for 1.5T and 0.71 for 3T. In the second radiologist it was 0.82 and 0.66, respectively. Three lesions (10%) were identified by general radiologists in non-specialized centers using a 1.5T standard protocol. In our center a consensus between two neuroradiologists using epilepsy protocol identified seven lesions (23%) using 1.5T and 10 (33%) using 3T (p Mención de responsabilidad : Lady D Ladino, Pedro Balaguera, Simon Rascovsky, Jorge Delgado, Juan Llano, Lizbeth Hernández-Ronquillo, Bety Gómez-Arias, José F Téllez-Zenteno Referencia : Rev Invest Clin. 2016 May-Jun;68(3):112-8. PMID : 27408997 En línea : http://clinicalandtranslationalinvestigation.com/abstract.php?id=86 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3945 Clinical Benefit of 3 Tesla Magnetic Resonance Imaging Rescanning in Patients With Focal Epilepsy and Negative 1.5 Tesla Magnetic Resonance Imaging [documento electrónico] / Lady Diana Ladino Malagón, . - 2016.
Obra : Revista de Investigación Clínica
Idioma : Inglés (eng)
Palabras clave : Epilepsy surgery lesional epilepsy magnetic resonance imaging partial epilepsy refractory epilepsy 3 Tesla Resumen : Background: Magnetic resonance imaging is an essential tool in the pre-surgical evaluation of patients with drug-resistant epilepsy. Objective: Our aim was to assess the value of re-imaging patients with focal drug-resistant epilepsy. Methods: Thirty patients with negative or non-conclusive 1.5 Tesla magnetic resonance imaging were rescanned with 1.5T and 3T. All of them had previous 1.5 scans with no seizure protocol in a non-specialized center. Two neuroradiologists who were blinded to prior imaging results randomly reviewed the magnetic resonance images. Kappa score was used to assess the reliability. Results: Mean age of patients was 30 (SD ± 11) years. The intra-observer agreement for the first radiologist was 0.74 for 1.5T and 0.71 for 3T. In the second radiologist it was 0.82 and 0.66, respectively. Three lesions (10%) were identified by general radiologists in non-specialized centers using a 1.5T standard protocol. In our center a consensus between two neuroradiologists using epilepsy protocol identified seven lesions (23%) using 1.5T and 10 (33%) using 3T (p Mención de responsabilidad : Lady D Ladino, Pedro Balaguera, Simon Rascovsky, Jorge Delgado, Juan Llano, Lizbeth Hernández-Ronquillo, Bety Gómez-Arias, José F Téllez-Zenteno Referencia : Rev Invest Clin. 2016 May-Jun;68(3):112-8. PMID : 27408997 En línea : http://clinicalandtranslationalinvestigation.com/abstract.php?id=86 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=3945 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000530 AC-2016-005 Archivo digital Producción Científica Artículos científicos Disponible